ArticleDiscover oncology2026
Transcriptome combined with single-cell data to construct a prognostic model for glycosylation-related genes in osteosarcoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiomics profiling of bone in the Dpp3-deficient mice unveils altered protein and lipid composition.Journal of endocrinological investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOsteosarcoma (OS) is a malignant primary bone tumor developing from primitive mesenchymal cells. Glycosylation is important in the adhesion, metastasis and transformation of cancer cells. Nevertheless, the investigation of glycosylation-related genes (GRGs) in OS has been infrequently described.
methodsThe OS-related datasets (GSE36001, TARGET-OS and GSE21257), scRNA-seq dataset (GSE152048) and 582 GRGs were contained in this research. The identification of candidate genes was conducted by differential expression analysis and weighted gene co-expression network analysis (WGCNA). The prognostic genes filtering method was univariate cox regression, and risk score were generated by the implementation of LASSO. Samples comprising the TARGET-OS and GSE21257 datasets were categorized into high- and low-risk according to the risk score. Through applying various cox regression analysis, independent prognostic variables were identified. Furthermore, functional enrichment analysis and immune microenvironment analysis were performed. Finally, the key cells were identified, and the cell-cell communication and pseudo-time analyses of key cells were conducted.
resultsThe analysis of scRNA-seq data identified cell types in OS and detected the expression of prognostic genes. Seven glycosylation-related genes (DCN, RENBP, UAP1, B4GALNT1, CCDC115, TUBA1A and B3GALT4) were identified as prognostic genes. The low-risk group exhibited a comparatively elevated rate of survival and 1-year OS patients had the highest survival rate. Immune and apoptosis-related signaling pathways were activated in the high-risk group, indicating a worse prognosis. The analysis of scRNA-seq data revealed DCN and TUBA1A were high- expressed in osteoblastic cells. Thus, the osteoblastic cells were identified as key cells. Osteoblastic cells exhibited frequent interactions with other annotated cells. Pseudo-time analysis elucidated the differentiation direction of key cells from left to right.
conclusionswe identified seven prognostic genes for OS. The prognostic models were constructed, and underlying molecular mechanisms were explored based on diagnostic genes, which served as a benchmark for OS prognosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.